Literature DB >> 2167979

Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor.

J L Galzi1, A Mejean, B Ilien, C Mollereau, J C Meunier, M Goeldner, C Hirth.   

Abstract

The synthesis of aryldiazonium and arylazido derivatives of carfentanil, etonitazene, and naltrexone and of a triazaspirodecane derivative is described. The chemical stability and the spectral characteristics of these compounds were verified, and their binding affinity constants for the different opioid receptor classes were determined, in the absence of light, from competition experiments. With the exception of the naltrexyl derivatives, which remained nonselective, all compounds tested displayed a pronounced mu-binding selectivity with mu/delta and mu/kappa ratios ranging from 12 to 1000. After irradiation, only the arylazido probes led to an irreversible mu-binding-site inactivation. This inactivation fulfilled the criteria for photoaffinity labeling such as protection against inactivation by other opiate ligands and absence of an effect of scavengers on the extent of the inactivation. Most of the photoactivatable probes formed long-lasting reversible complexes with the opioid binding sites: an efficient dissociation procedure was thus required to discriminate between pseudoirreversible and covalent complexes. The marked differences in labeling efficacy between aryldiazonium salts and their corresponding arylazido derivatives are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167979     DOI: 10.1021/jm00171a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.

Authors:  Dong Jin Hwang; Jun Yang; Huiping Xu; Igor M Rakov; Michael L Mohler; James T Dalton; Duane D Miller
Journal:  Bioorg Med Chem       Date:  2006-07-07       Impact factor: 3.641

2.  A convenient route to 4-carboxy-4-anilidopiperidine esters and acids.

Authors:  János Marton; Brita Glaenzel; Julia Roessler; Daniela Golaszewski; Gjermund Henriksen
Journal:  Molecules       Date:  2012-03-07       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.